Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glenveigh Medical
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
AI/ML Grows In Importance, Holds Promise in mRNA
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
- In Vitro Diagnostics
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Glenveigh Pharmaceuticals, LLC
- Glenveigh Surgical
- Glenveigh Research
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.